Clinical Trial Update: Expanded Access Program for Treatment With Ecopipam for Tourette's Disorder

View source ↗

Summary

Emalex Biosciences announces an expanded access program for Ecopipam to treat Tourette syndrome, indicating the program is available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tourette Syndrome

Drugs mentioned

• Ecopipam (Ecopipam)

Snippet

Sponsor: Emalex Biosciences Inc. | Conditions: Tourettes Disorder, Tourette Disorder | Status: AVAILABLE